Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Recommendation of “Hold” by Brokerages

Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) have been given a consensus recommendation of “Hold” by the twelve brokerages that are covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $8.6250.

Several research firms have commented on IOVA. The Goldman Sachs Group reiterated a “sell” rating and issued a $2.00 target price on shares of Iovance Biotherapeutics in a research report on Thursday, February 5th. Wall Street Zen upgraded shares of Iovance Biotherapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Citizens Jmp raised shares of Iovance Biotherapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 target price on the stock in a report on Wednesday, February 25th. Barclays raised their price target on shares of Iovance Biotherapeutics from $10.00 to $11.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Finally, Chardan Capital reduced their price objective on shares of Iovance Biotherapeutics from $17.00 to $16.00 and set a “buy” rating on the stock in a research note on Wednesday, February 25th.

Institutional Investors Weigh In On Iovance Biotherapeutics

A number of institutional investors have recently made changes to their positions in the stock. Vontobel Holding Ltd. bought a new position in shares of Iovance Biotherapeutics during the third quarter worth about $26,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Iovance Biotherapeutics during the 3rd quarter valued at approximately $27,000. Arcataur Capital Management LLC acquired a new stake in Iovance Biotherapeutics during the 4th quarter valued at approximately $29,000. Granite Investment Partners LLC bought a new position in Iovance Biotherapeutics during the 4th quarter worth approximately $29,000. Finally, Motley Fool Asset Management LLC acquired a new position in shares of Iovance Biotherapeutics in the 4th quarter worth approximately $29,000. Institutional investors own 77.03% of the company’s stock.

Iovance Biotherapeutics Stock Performance

NASDAQ IOVA opened at $3.79 on Tuesday. The firm’s fifty day moving average price is $2.74 and its two-hundred day moving average price is $2.44. The stock has a market cap of $1.56 billion, a PE ratio of -3.38 and a beta of 0.68. Iovance Biotherapeutics has a fifty-two week low of $1.64 and a fifty-two week high of $4.57.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.04. The company had revenue of $86.77 million for the quarter, compared to the consensus estimate of $81.61 million. Iovance Biotherapeutics had a negative return on equity of 54.54% and a negative net margin of 148.41%. As a group, sell-side analysts predict that Iovance Biotherapeutics will post -1.24 earnings per share for the current fiscal year.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.